10/02/2024

RespirAI Medical Signs “Know-How”...

RespirAI Medical Signs “Know-How” Agreement with Mayo Clinic, Receives Grant from IIA

Take a moment to pause and appreciate the simple act of breathing. For those grappling with chronic respiratory diseases, every breath can be a battle.  

 

EHV portfolio company RespirAI Medical is bridging the gap in respiratory care through cutting-edge AI technology. They are transforming the management of chronic respiratory diseases with an innovative AI-based home monitoring platform. 

 

The first chosen indication of RespirAI platform is COPD, which affects more than 300 million patients globally, mainly ex-smokers. It is the only chronic disease that is still on a rise in the US today, and the third leading cause of death worldwide, with over 3 million deaths every year. It’s also a massive burden on healthcare systems with more than $20 billion of direct healthcare costs in the U.S alone 

 

Co-founded by Nimrod Bin-Nun, CEO and Assaf Gur, VP R&D, the young startup has achieved many impressive accomplishments since joining the incubator in 2022. The company has recently completed their first clinical trial at Assuta Ashdod University Hospital. There, they assessed the technology on COPD patients and the results were very promising. 

 

Currently, RespirAI is embarking on a multisite clinical trial spanning several leading hospitals, including Tel Aviv Sourasky Medical Center, Soroka Medical Center, and Assuta Ashdod University Hospital. This phase will focus on finalizing the platform development. 

They have just been approved for their second grant from the Israel Innovation Authority for $400K. Recently, the company signed on a “know-how” agreement with Mayo Clinic for developing its second indication for monitoring COPD rehabilitation process. 

 

RespirAI’s outstanding work has earned them a spot as finalists in JVP’s Digital Health Accelerator in Haifa, a testament to their innovation and dedication.   

 

Breathing should never be a luxury, and thanks to companies like RespirAI, it’s becoming a reality. Let’s wish them successes on their journey to improving lives and creating a healthier future for all.

About eHealth Ventures

The eHealth Ventures partnership is a leading investor in early-stage digital health companies.
It includes 2 VC funds and a technological incubator with an exclusive focus on digital health and significant government non-dilutive funding. Partners include Maccabi (a leading Israeli HMO), Amgen (global biotech giant), the Mayo Clinic, Medison Ventures, Arad Investments, and the Hadar Group. The team has reviewed over 1,650 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care and Bioconvergence).

Get in Touch